Guanylyl cyclase C as a biomarker in colorectal cancer

ISSN： 1752-0363

Source： Biomarkers in Medicine, Vol.7, Iss.1, 2013-02, pp. : 159-167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases

NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol. 27, Iss. 8, 2015-08 ,pp. : 1057-1068

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dietary and biomarker estimates of fatty acids and risk of colorectal cancer

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 5, 2015-09 ,pp. : 1224-1234

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intensive Radiographic and Biomarker Surveillance in Stage II and III Colorectal Cancer

Oncology, Vol. 82, Iss. 1, 2012-01 ,pp. : 41-47

Karger

Access to resources Recommend Favorite

The fibrate gemfibrozil is a NO‐ and haem‐independent activator of soluble guanylyl cyclase: in vitro studies

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 9, 2015-05 ,pp. : 2316-2329

John Wiley & Sons Inc

Access to resources Recommend Favorite

FABP4 is secreted from adipocytes by adenyl cyclase‐PKA‐ and guanylyl cyclase‐PKG‐dependent lipolytic mechanisms

OBESITY, Vol. 23, Iss. 2, 2015-02 ,pp. : 359-367

John Wiley & Sons Inc

Access to resources Recommend Favorite